These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30116680)

  • 1. Generalized Edema Caused by Albiglutide: A Case Report.
    Aziz K; Shahbaz A; Zarghamravanbakhsh P; Ahmed SI; Sachmechi I
    Cureus; 2018 Jun; 10(6):e2801. PubMed ID: 30116680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albiglutide for the management of type 2 diabetes.
    Rendell MS
    Expert Rev Endocrinol Metab; 2018 Jan; 13(1):1-8. PubMed ID: 30063441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes.
    Setji T; Feinglos M
    Expert Rev Endocrinol Metab; 2013 May; 8(3):229-238. PubMed ID: 30780810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albiglutide: a unique GLP-1 receptor agonist.
    Rendell MS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1557-1569. PubMed ID: 27677385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
    Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
    Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albiglutide for the treatment of type 2 diabetes.
    Muscogiuri G; Gastaldelli A
    Drugs Today (Barc); 2014 Oct; 50(10):665-78. PubMed ID: 25374965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.
    Woodward HN; Anderson SL
    Patient Prefer Adherence; 2014; 8():789-803. PubMed ID: 24926194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
    Davis PN; Ndefo UA; Oliver A; Payton E
    Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY.
    Doggrell SA
    Expert Rev Endocrinol Metab; 2015 May; 10(3):273-276. PubMed ID: 30298769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
    Brønden A; Knop FK; Christensen MB
    Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albiglutide: a review of its use in patients with type 2 diabetes mellitus.
    Blair HA; Keating GM
    Drugs; 2015 Apr; 75(6):651-63. PubMed ID: 25777969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal safety across the albiglutide development programme.
    Leiter LA; Mallory JM; Wilson TH; Reinhardt RR
    Diabetes Obes Metab; 2016 Sep; 18(9):930-5. PubMed ID: 27097971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
    Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
    Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
    Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
    Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
    Lepore JJ; Olson E; Demopoulos L; Haws T; Fang Z; Barbour AM; Fossler M; Davila-Roman VG; Russell SD; Gropler RJ
    JACC Heart Fail; 2016 Jul; 4(7):559-566. PubMed ID: 27039125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.
    Young MA; Wald JA; Matthews JE; Scott R; Hodge RJ; Zhi H; Reinhardt RR
    Postgrad Med; 2014 Nov; 126(7):84-97. PubMed ID: 25387217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes.
    Matthews JE; Reinhardt RR; Carr MC
    Postgrad Med; 2016 May; 128(4):391-7. PubMed ID: 27043162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
    Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.